An extraordinary hearing is underway by the House Oversight Committee, which is investigating the role of opioid painkiller manufacturer Pardu Pharma, the manufacturer of the prescription narcotic oxycontin.
The hearing is titled, “The Role of Purdue Pharma and the Saxon Color Family in Audioid Epidemics.”
Purdue pleaded guilty in federal court last month to crimes related to the io pioid crisis that killed nearly half a million Americans.
However, the clutch of members of the billionaire Secular family, which owns a private company, was not charged, although they are being investigated.
The company and six members of the family are based in several U.S. cities and counties and U.S. No. has been claimed by many states.
Caroline b. Maloney
(2 reps)The Suck Color family and Purdue Pharma helped fuel fuel, starting with the billion dollar opioid epidemic. Tune in to watch today @ OversightDams Suclian W / sack tax family members and CEO of Purdue. https://t.co/L2Mgt9tVqc
One of the reasons this hearing is extraordinary is that two of those suckers agreed to testify voluntarily today, which is very unusual. They talk very, very rarely about Purdue and their role in xy xanthine and io pioid crises.
Today, Kathe sack color, The former vice president of Purdue, who was on the company’s board from 1990 to 2018, is appearing (remotely) to testify. She is the daughter of one of Pardu’s co-founders.
There is also testimony David Sack Color, The grandson of one of the co-founders and the son of Richard Sack Color, who was president of Pardu for many years. David Sackler was on the Purdue board from 2012 to 2018. Purdue CEO Craig Lando is also testifying.
Committee Chairman Caroline MaloneyThe Democratic Congressional Woman of New York said: “No member of the S Color family has ever confessed to doing anything wrong, or taken responsibility, or apologized. They have not accepted any responsibility. ”
But she called it the io pioids crisis, driven by powerful prescription opioids, especially oxycontin “crime against the American people.”
Purdue Pharma is currently appearing before a New York bankruptcy court, which placed itself in Chapter 11 bankruptcy defense in September 2019, to prevent litigation, prevent further proceedings and settle with the plaintiff.
The drawn proceedings are not yet complete and many aspects of the futures of the company and family members remain in the air, awaiting the decision of the bankruptcy judge.
.
